Proof-of-principle investigation of an algorithmic model of adenosine-mediated angiogenesis by Azuaje, Francisco et al.
RESEARCH Open Access
Proof-of-principle investigation of an algorithmic
model of adenosine-mediated angiogenesis
Francisco Azuaje
1*, Frédérique Léonard
1, Magali Rolland-Turner
1, Yvan Devaux
1 and Daniel R Wagner
1,2
* Correspondence: Francisco.
Azuaje@crp-sante.lu
1Laboratory of Cardiovascular
Research, Centre de Recherche
Public - Santé (CRP-Santé), L-1150,
Luxembourg, Luxembourg
Full list of author information is
available at the end of the article
Abstract
Background: We investigated an algorithmic approach to modelling angiogenesis
controlled by vascular endothelial growth factor (VEGF), the anti-angiogenic soluble
VEGF receptor 1 (sVEGFR-1) and adenosine (Ado). We explored its feasibility to test
angiogenesis-relevant hypotheses. We illustrated its potential to investigate the role
of Ado as an angiogenesis modulator by enhancing VEGF activity and antagonizing
sVEGFR-1.
Results: We implemented an algorithmic model of angiogenesis consisting of the
dynamic interaction of endothelial cells, VEGF, sVEGFR-1 and Ado entities. The model
is based on a logic rule-based methodology in which the local behaviour of the cells
and molecules is encoded using if-then rules. The model shows how Ado may
enhance angiogenesis through activating and inhibiting effects on VEGF and sVEGFR-
1 respectively. Despite the relative simplicity of the model, it recapitulated basic
features observed in in vitro models. However, observed disagreements between our
models and in vitro data suggest possible knowledge gaps and may guide future
experimental directions.
Conclusions: The proposed model can support the exploration of hypotheses about
the role of different molecular entities and experimental conditions in angiogenesis.
Future expansions can also be applied to assist research planning in this and other
biomedical domains.
Background
Angiogenesis, the generation and development of new blood vessels from existing ones,
is a fundamental complex process in health and disease [1,2]. The evolution of new
blood vessel networks may be defined as the by-product of the division and migration
of endothelial cells (ECs) in response to different physiological molecular conditions or
pathological stress stimuli. Hypoxia, the deprivation of oxygen delivery to a tissue, is
among such angiogenesis-triggering conditions. Hypoxia-induced angiogenesis is criti-
cal in the understanding of mechanisms underlying the evolution of tumours and car-
diac damage. Angiogenesis requires the molecular signalling interplay between a
plethora of growth factors, anti-angiogenic molecules and environmental stimuli [1].
Vascular endothelial growth factor (VEGF) is one of the most potent pro-angiogenic
molecules activated in hypoxic conditions. VEGF binds to several receptors, such as
the membrane-associated receptor VEGFR-1 or fms-like tyrosine kinase 1 (Flt1). A
soluble form of VEGFR-1 (sVEGFR-1) traps circulating VEGF and prevents its binding
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any medium, provided the original work is properly cited.to membrane receptors, thereby acting as a decoy receptor having anti-angiogenic
properties [2,3]. This is a typical example of a molecule sharing dual roles in angiogen-
esis according to specific intra- and extra-cellular localization [4,5].
In silico models of angiogenesis have been investigated in unicellular and multi-cellu-
lar contexts chiefly through the implementation of numerical approaches, i.e. differen-
tial reaction equations [6,7]. Computational or algorithmic models define a second
family of approaches. These are based on operational descriptions of molecular interac-
tions and processes, e.g. sets of if-then rules, which are used to dynamically encode and
execute the models [8,9]. Unlike traditional mathematical models, such as those based
on reaction equations, algorithmic models can incorporate dynamic visualization cap-
abilities at the individual cellular and tissue levels. Moreover, algorithmic models can
integrate specific causal mechanistic information at the cell or multi-cell levels.
Another key reason for selecting this methodology was that it does not require the
precise approximation of mathematical parameters, such as concentration rates, which
are required in traditional reaction models. This is particularly relevant to our problem
due to the relative lack of quantitative information to allow us to implement more
detailed models. Furthermore, at this stage we are mainly interested in assessing its
potential as a simulation-based exploratory tool.
In silico models, in general, can recreate or mimic the initiation and development of
blood vessel networks in different medically-relevant scenarios [10,11]. Mathematical
and computational models have received relatively greater attention in the area of can-
cer research [12-15]. Within this area, several computational models based on cellular
automata or agent-based systems have been proposed [13,15-19], which approximate
diverse structural and functional aspects of cellular growth or angiogenesis. Further-
more, there is a need to implement models relevant to other biomedical settings,
including those in which angiogenesis can play protective or therapeutic functions, e.g.
myocardial infarction.
Our research group investigates the role of angiogenesis in the context of cardiac
disease. In particular, we are interested in studying the regulation of angiogenesis to
promote the treatment and repair of the ischemic heart. Apart from investigating the
dynamic interaction between known pro- and anti-angiogenic factors, we aim to char-
acterize the modulating effects of cardio-protective factors, such as adenosine (Ado).
Previous research has shown how Ado can promote angiogenesis in ischemic tissue
[16,20]. Moreover, Ado has been found to drive ECs proliferation, migration and sub-
sequent vessel network development in the heart [21-23]. We and others have reported
that Ado controls VEGF expression and activity [23-29]. We hypothesized that the
effect of Ado on VEGF pathway may be a more complex phenomenon than simply an
enhancement of expression. Therefore, to guide future in vitro experimental develop-
ments, we set out to investigate the roles that VEGF, sVEGFR-1 and Ado can play in
angiogenesis using an algorithmic exploratory model.
We introduce here a computational model of sprouting angiogenesis in which the
ECs divide and move to generate complex vascular networks through the integrated
effect of VEGF and sVEGFR-1. We also tested the hypothesis that Ado promotes
angiogenesis by simultaneously enhancing VEGF and reducing sVEGFR-1 activity. Our
model mimics the generation of vascular networks under different experimental condi-
tions, and enables the visualization of branching patterns and systems-based
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specified and implemented as a “rule-based” system, in which thousands of ECs and
molecules autonomously and locally interact following fundamental mechanistic princi-
ples encoded as “if-then” rules. Such an interaction is performed in parallel to give rise
to the observed emergent behaviours at the multi-cellular level. Our model can actually
be defined as one belonging to the category of agent-based models (also known as
individual-based models). Key features of this category are the heterogeneity of spatial
states, the diversity of model components and their behaviours, and the application of
decision-making rules at the local control level only.
We quantitatively assessed the effects and relationships between the model compo-
nents, and generated testable predictions. These analyses were followed by in vitro
experiments as a first step to estimate potential biological relevance and feasibility of
the proposed computational model. In principle, the computational model enabled us
to verify different hypotheses and led us to a deeper biological understanding. The
results also provided insights that may suggest a possible reformulation of some
aspects of our hypothesis about the combined effects of Ado, VEGF and sVEGFR-1.
Methods
Model foundations and study phases
A pivotal conceptual premise of our model is that the individual behaviour of the bio-
logical entities (ECs, VEGF, sVEGFR-1, Ado) may be synthesized by a set of algorith-
mic rules. Such rules specify the entities’ local behaviour in response to the state of
other entities and the environment. Thus, the rules encapsulate biological hypotheses
about entity interactions (cell-cell, cell-molecule or cell-environment) in a computing
format suitable to dynamic simulations. The rules are applied to each entity to update
its state in a time- and space-specific fashion. Each state update may trigger the divi-
sion and/or movement of an entity. At local and individual entity levels, such rule-
driven transformation processing has little dynamic predictive value. However, the
integration of individual entity behaviours in time and space leads to angiogenesis-like,
branching patterns. This also means that in our models there is no specification or
centralized control of global or collective behaviour. Our entities update their states
only in response to their local environment (spatial neighbourhood, see Computational
model specification).
In our models, a rule specifies the actions of an entity in response to its own (cur-
rent) state or the state of its neighbourhood based on conditional programming state-
ments. The application of such logic rules and the resulting transformation are
conducted following a stochastic (non-deterministic) scheme. This stochastic behaviour
is defined by a probability of actually executing the rule, which encodes the notion of
random motility and response heterogeneity of biological entities [29,30]. The spatial
environment is represented by a 2D grid (a matrix of m × n sites). Boolean variables
are used to represent the presence or absence of an entity in each grid site. Such a
grid can be interpreted as the digital, though rough, equivalent of a Matrigel assay, i.e.
our angiogenesis in vitro assay. In our model, time is represented by simulation cycles.
In each cycle, the system executes all the model rules and updates all entity states at
each grid site. Each simulation (experiment) consists of a pre-specified number of
cycles (see computational model specification).
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Page 3 of 20Figure 1 is a cartoon diagram of our angiogenesis model consisting of four entities:
EC, VEGF, sVEGFR-1 and Ado. This illustration is better interpreted from the bottom
to the top. Arrows are used to indicate EC division and migration to a new site. At the
beginning of a simulation, an initial set of ECs forms the “initial vessel”, located at the
bottom of the grid. The other entities are randomly distributed on the grid, which can
be seen as the equivalent of an isotropic distribution of molecules at the start of an in
vitro experiment. An EC “divides” and “moves” to a new site If aV E G Fe n t i t yi sp r e -
sent And as V E G F R - 1i sa b s e n ti nt h ei m m e d i a t eE C ’s neighbourhood. Thus, a
sVEGFR-1 will inhibit the birth of a new EC (symbolised in the figure with an arrow
crossed with an X). Similarly, an EC can divide and move to a new site If Ado is pre-
sent in the immediate EC’s neighbourhood, independently of the presence of sVEGFR-
1 (right side of figure). This defines a central hypothesis of our model: Ado promotes
angiogenesis by enhancing VEGF activity and by antagonizing sVEGFR-1. This is
because the presence of Ado would allow VEGF to exert its effect on EC indepen-
dently of the presence of inhibitors. For additional information on design principles
and computing implementation of rule-based or algorithmic models the reader may
refer to [31,32].
Figure 2 summarizes the different phases of our investigation. In the first phase,
model verification, we implemented a foundation angiogenesis model in which EC
growth is controlled by VEGF and sVEGFR-1 only. Thousands of simulations allowed
us to test different experimental conditions, i.e., different VEGF and sVEGFR-1 con-
centration values. This phase resulted in the definition of biologically plausible, cali-
brated models both in terms of the predicted outcomes (e.g., resulting angiogenic-like
Figure 1 Cartoon diagram of our angiogenesis model. Model consisting of four entities: EC, VEGF,
sVEGFR-1 and Ado. Sequence of events is visualised from the bottom to the top of the figure. Arrows are
used to indicate EC division and migration to a new site.
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the control model settings that were needed in subsequent research phases. In the pre-
diction phase we tested the Ado-mediated angiogenesis hypothesis. Moreover, we con-
ducted independent experiments in which the effects of adding sVEGFR-1, Ado and
variable proportions of both entities were estimated. As an initial step to estimate the
potential biological utility of our computational approach, we carried out in vitro
experiments using culture media of preconditioned human primary macrophages trea-
t e d( a n du n t r e a t e d )w i t hA d oo naM A T R I G E Lc u l t u r e dh u m a nc o r o n a r ya r t e r y
endothelial cells (HCAEC) model. This was done in the presence (and absence) of
additional exogenous sVEGFR-1. Although this phase does not actually represent an
experimental validation of the model, it allowed us to compare the predicted global
effects of added sVEGFR-1, Ado and combined Ado/sVEGFR-1 (relative to control
conditions) with in vitro observations obtained at our laboratory.
Computational model specification
Figure 3 illustrates the main design components and processes of the models. The con-
cept of EC neighbourhood is further illustrated with a cartoon representation involving
the model entities. Arrows are used (Figure 3A) to show the directions in which an EC
can move at a particular cycle step. The model is based on the interaction of 4 mole-
cular entities: EC, VEGF, sVEGFR-1 and Ado. Two logical rules were independently
implemented and investigated for different numerical parameters. The first rule (R1) in
Figure 3B encodes the behaviour of EC, VEGF and sVEGFR-1 in control conditions
only (Model Verification Results). The second rule (R2) defines the Ado-mediated
model investigated. The input parameters of each simulation are: grid area size (grid-
Area, m × n sites on the grid), initial number of ECs (iniEC), number of VEGF entities
(VEGF), number of sVEGFR-1 entities (sVEGFR-1), number of Ado entities (Ado),
number of simulations (numSim), number of cycles per simulation (numCycles) and
Figure 2 Experimental and analytical phases of our investigation.
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effective rule execution). The iniEC parameter defines the length of the initial vessel
located at the bottom of the grid (sprouting vessel). The output of each model simula-
tion was assessed on the basis of the resulting vessel network area: numECs/gridArea,
with numECs representing the total numbe ro fE C so b s e r v e da tt h ee n do fas i m u l a -
tion. The output of sets of simulations was summarized with their mean values. Figure
3C describes the main steps implemented in a single simulation. After model para-
meters have been initialized, a simulation cycle starts by the application of the model
rules to each site on the grid. After all entity states have been adapted, molecular
Figure 3 Model specification. A. Definition of the concept of EC neighbourhood. Arrows indicate the
direction of possible moves of an EC at a particular step cycle. B. Definition of main model parameters and
variables: Entities, model rules, input parameters, and output variables. Rules R1 and R2 were independently
implemented in systems verification and prediction phases. C. Flow chart summarising model algorithm.
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bour site randomly chosen. This diffusion process only applied to VEGF, sVEGFR-1
and Ado. These steps are repeated for numCycles.
In silico experiments: implementation and execution
The models reported in this paper were implemented with the following input para-
meters: gridArea = 90E3 (300 × 300), iniEC = 300, numCycles = 300, numSim = 1000
and P = 0.05. Quantitative responses to different levels and relative proportions of
VEGF, sVEGFR-1 and Ado were investigated as shown above. The reported simula-
tions were implemented with 300 cycles/simulation. In ideal cell-growth conditions,
this would be sufficient to allow the tip of a network to reach the top of the grid in a
single simulation, i.e., maximum grid length. However, larger numbers of cycles
reported very similar overall responses to those observed in models with numCycles =
300. This may be an indication of steady state response. To exemplify this point, Addi-
tional file 1 illustrates results from the Ado-treatment setting with numbers of cycles
ranging from 300 to 1500.
In vitro experiments
Cell culture: Peripheral blood mononuclear cells (PBMCs) from healthy volunteers (1
sample/person) were isolated by Ficoll gradient. Monocytes were purified by negative
selection using the Monocyte Isolation Kit II (Myltenyi Biotec GmbH, Bergisch Glad-
bach, Germany) as described before [33]. Differentiation was achieved by adding 50
ng/mL M-CSF for 7 days. The obtained macrophages were then incubated with Ado
and EHNA (10 μmol/L) (Sigma, Bornem, Belgium) to prevent Ado metabolism. LPS
(from Escherichia coli 026:B6)) (Sigma) was used as cell activator. Conditioned med-
ium was harvested and stored at -80°C until use.
In vitro angiogenesis assay: Human Coronary Artery Endothelial Cells (HCAEC,
Lonza, Verviers, Belgium) were seeded on Growth Factor Reduced Matrigel™ (BD
Bioscience, Erembodegem, Belgium) coated 48-well plates. Culture medium was made
of a 1/1 mix of EBM2 medium (Lonza) containing 2% of Fetal Calf Serum and condi-
tioned medium from macrophages treated with LPS and/or Ado as described above. In
some cases, 10 ng/mL of sVEGFR-1 (R&D Systems, Oxon Abingdon, UK) was added
in this culture medium 1 hour before the contact with HCAEC. After six hours, the
formation of microtubules by HCAEC was blindly measured by three different investi-
gators on three microscopic fields per culture well. This formation was evaluated by
measurement of the vascular surface area using Aïda software (Kodak, Zaventem,
Belgium).
Ethics Statement
The sample acquisition protocol was approved by the local ethics committee (Comité
National d’Éthique de la Recherché, CNER) and written informed consent was
obtained from all volunteers.
Statistics and software
Mean-based comparisons between independent groups were carried out with t-tests,
and 95% confidence intervals were calculated around estimated means. Statistical
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Java programming language.
Results
Model verification
Experiments involving variable values of VEGF and sVEGFR-1 (R1, in Figure 3) pro-
duced biologically-consistent graphical outcomes and quantitative measurements. Fig-
ure 4 summarizes this first set of simulations. In each experimental setting 1000
simulations were implemented, each consisting of 100 cycles. The graphical outputs of
these simulations recreate the branching and sprouting patterns observed in blood ves-
sel network development. Similarly, the quantitative relationships observed between
VEGF, sVEGR-1 and (mean) vessel network area are consistent with the expected
responses: a. the higher the value of VEGF, with sVEGFR-1 constant, the larger the
area covered by the resulting network (Figure 4A); b. the higher the value of sVEGFR-
1, with VEGF constant, the smaller the observed network area (Figure 4B). Each panel
also portrays snapshot examples of networks observed at the end of single simulations
for various VEGF and sVEGFR-1 values. Figure 5 illustrates a close-up view of a simu-
lation outcome.
Next, we aimed to implement models with more biologically-plausible VEGF and
sVEGFR-1 values. This was done by focusing on experiments in which the sVEGFR-1/
VEGF ratio was equal to 1/5, which is comparable to baseline values observed in in
vitro control experiments. Figure 6 shows simulation results for several experimental
settings, including examples of snapshots of graphical outcomes. As expected, vessel
areas tend to proportionally and linearly depend on increases of both VEGF and
sVEGFR-1 values, when sVEGFR-1/VEGF = 1/5. These experiments allowed us to pro-
pose a calibrated, biologically-plausible model that can be used as a control setting for
subsequent analyses. We decided to focus on an experimental setting with VEGF =
40000 and sVEGFR-1 = 8000 as our control (or reference) model. This is a suitable
selection because: a. it is based on a feasible concentration ratio value, b. its graphical
outputs are sufficiently interpretable, and c. it leaves room (grid area) for possible sig-
nificant enlargements or reductions in vessel network sizes in succeeding experiments.
Model predictions
We used the model to predict the effects of dynamically increasing sVEGFR-1 levels on
vessel network development (R1, in Figure 3). Figure 7 illustrates representative quanti-
tative and graphical results for different sVEGFR-1 values. The predicted outputs were
compared to those obtained from control experiment (Figure 7A). As anticipated, the
addition of sVEGFR-1 leads to reduction of vessel areas. However, significant depar-
tures from the mean area obtained under control conditions were detected when
sVEGFR-1>1000 (experiment vs. control, t-tests, P < 1E-6). Smaller incremental
changes were obtained when sVEGFR-1 ≥ 40000, suggesting a saturation of network
reduction capacity.
Next we implemented independent sets of simulations to test the model involving
exogenously added Ado (R2, in Figure 3). Our model does not incorporate endogenous
Ado entities. This simplification is justified by the conditions of our in vitro experi-
ments, which indicate that the level of endogenous Ado is much smaller than
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Page 8 of 20Figure 4 Relationship between molecule concentration values and vessel network areas.I l l u s t r a t i v e
examples of A. sVEGFR-1 = 10000 and VEGF variable. B. VEGF = 10000 and sVEGFR-1 variable. Panels show
examples of snapshots of graphical outputs of simulations.
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as EHNA (Methods), are added to the cell cultures, endogenous Ado accumulated in
the medium is recycled towards AMP with the help of adenosine kinase [35]. There-
fore, in the absence of cell breakdown or ischemia, the concentration of endogenous
Ado is very low in cell cultures, including those composed of cardiac myocytes. As
hypothesized and in comparison to controls, vessel area is increased by adding Ado
(Figure 8). Such a difference was statistically significant (experiment vs. control, t-tests,
P < 1E-6). Furthermore, and unexpectedly, such a tendency was observed even in con-
ditions when added sVEGFR-1 was as twice as large as Ado (Figure 7A, second point
on plot). Saturation of vessel area growth capacity appears to occur after Ado > 8000.
We further investigated the interplay between added sVEGFR-1 and Ado (combined)
levels in biologically-viable conditions (R2, in Figure 3). We measured responses to dif-
ferent dynamic ranges of sVEGFR-1 and Ado under a sVEGFR-1/Ado ratio of 2 (Fig-
ure 9). This ratio conservatively mirrors the observation that in a single in vitro
experiment sVEGFR-1 levels are larger, on average, than Ado levels (Discussions). Fig-
ure 9 corroborates the in silico findings reported above: adding Ado to the system
results in increases of vessel network area in relation to controls, independently of
added sVEGFR-1 levels for the proportions investigated. Such increases can be
Figure 5 Close-up view of a simulation outcome. VEGF = 10000, sVEGFR-1 = 50000.
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Page 10 of 20Figure 6 Representative simulation results of biologically-plausible models. Quantitative relationships
and examples of output snapshots for different values of VEGF and sVEGFR-1, with sVEGFR-1/VEGF = 1/5.
Model based on VEGF = 40000 and sVEGFR-1 = 8000 was chosen as a control model for implementing
subsequent experiments.
Figure 7 Representative examples of effects of dynamically increasing sVEGFR-1 levels on vessel
network development. A. Vessel areas in response to different sVEGFR-1 values in comparison to control
conditions (VEGF = 40000, sVEGFR-1 = 8000). B. Examples of simulation output snapshots.
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to control VEGF levels. For Ado > 5000 and sVEGFR-1 > 8000, such differences are
statistically detectable (control vs. experime n t s ,t - t e s t s ,P<1 E - 6 ) .S t r o n gd i f f e r e n c e s ,
i.e., reductions, in terms of mean vessel areas between (pair-wise) experimental condi-
tions were also detected (P < 1E-6), though less pronounced than the differences
between these experiments and the controls.
Adenosine effects on network reach
Next we examined network “reach”. This estimates how far a newly formed network
can reach out from the initial vessel, i.e., the distance from the initial network to the
farthest network tip. Thus, network reach also reflects the maximum branch length.
Figure 8 Representative simulation results from Ado-mediated model. A. Vessel areas in response to
different Ado values compared to control conditions. B. Examples of simulation output snapshots.
Figure 9 Representative simulation results from models with different sVEGFR-1 and Ado values
and sVEGFR-1/Ado = 2. A. Vessel areas in response to increasing sVEGFR-1 and Ado values compared to
control conditions. B. Examples of simulation output snapshots.
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in comparison to the control setting. Results followed the same tendency observed in
the case of network areas (Figure 10). Moreover, area and reach response are strongly,
positively correlated in Ado-added experimental settings (Spearman correlation > 0.2,
P < 0.05).
Follow-up, exploratory in vitro experiments
As a starting point to motivate further development of the proposed computational
model, we performed in vitro experiments using HCAECs in a Matrigel angiogenesis
assay. The principle of this assay is to culture HCAEC in a conditioned medium from
macrophages together with different treatments. The effect of the treatments on angio-
genesis is measured by the surface of the culture dish occupied by microtubules
formed by endothelial cells. We aimed to quantitatively compare the results obtained
in vitro with this assay to our computational predictions on the basis of the observed
vessel areas only (Figure 11).
Three in vitro experiments were completed in each of the following conditions:
added sVEGFR-1, added Ado, and added combination of Ado and sVEGFR-1. In Fig-
ure 9, these experiments are referred to as sVEGFR-1(+), Ado(+) and Ado/sVEGFR-1
(+) respectively. In vitro vessel areas were estimated in an automated fashion using
densitometric analysis. In vitro control condition involved VEGF ~ 50 pg/mL and
sVEGFR-1~ 10 pg/mL. The following values defined the experimental conditions: Ado
(+) = 10 μmol/L and sVEGFR-1(+) = 10 ng/mL. The set of in silico experiments
included here for comparison were implemented as follows: Control (VEGF = 40000
and sVEGFR-1 = 8000); added sVEGFR-1: VEGF = 40000, sVEGFR-1 = 20000; added
Ado: VEGF = 40000, sVEGFR-1 = 8000, Ado = 4000; added combination of Ado and
sVEGFR-1: VEGF = 40000, sVEGFR-1 = 20000, Ado = 10000. Similar correlation
trends can be observed for different absolute values of sVEGFR-1 and Ado using con-
trol as a reference. Although we cannot state that there is a biologically-specific, one-
to-one connection between these in silico parameters and their in vitro counterparts,
we chose them for comparison purposes as they did not generate extreme simulation
outcomes, i.e., neither maximum nor minimum network areas. Moreover, they are
based on the biologically-feasible models presented above.
Figure 10 T h ee f f e c to fA d oo nn e t w o r kr e a c h . Network reach in response to different Ado values
compared to control conditions.
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vitro and in silico results (Spearman correlation = 0.4) across the different experimental
conditions (Figure 11). As expected, in relation to control conditions, in both systems
the incorporation of additional sVEGFR-1 induced a reduction of angiogenesis. Simi-
larly, added Ado caused the formation of networks of larger areas.
Figure 11 Comparison of in silico and in vitro experiments. A. Quantitative relationships between in
silico and in vitro experiments across different experimental conditions on the basis of estimated vessel
areas. Data are normalized to corresponding control mean vessel areas (points and bars: mean values of
vessel areas ± 95% confidence interval). sVEGFR-1(+): added sVEGFR-1, Ado(+): added Ado, Ado(+)/sVEGFR-
1(+): added combination of Ado and sVEGFR-1. B. Snapshot examples of the formation of (in vitro)
microtubule networks in experiments using primary human coronary artery endothelial cells (HCAEC), and
conditioned medium from macrophages stimulated for 24 hours by 100 ng/mL lipopolysaccharide. In vitro
control condition: VEGF ~ 50 pg/mL, sVEGFR-1~ 10 pg/mL. Experimental conditions: Ado(+): 10 μmol/L,
sVEGFR-1(+): 10 ng/mL.
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reduction of mean vessel areas with respect to Ado(+) experiments. However, such a
reduction was notoriously larger in the in vitro experiments. In contrast to the in silico
model, we observed a mean vessel area below that obtained in control conditions.
Although the small number of in vitro experiments represent a limitation to a more
accurate quantitative comparison, such an in vitro vs. in silico difference was statisti-
cally detectable at P = 1E-3. This discrepancy may suggest new research directions or
limitations of our computational model (Discussion). Figure 11B depicts examples of
graphical snapshots of different in vitro experimental conditions.
Discussion
Previous research has shown the potential pro-angiogenic role of Ado and its clinical
relevance to heart disease [23-25]. Here we reported computational, rule-based
dynamic simulations of angiogenesis in which Ado, as well as known ECs growth pro-
moting and inhibiting factors, were modelled to investigate biologically-meaningful
responses. In addition, our findings point to possible new research directions in this
area. In particular, we tested in silico the hypothesis that Ado may step-up angiogen-
esis through supporting VEGF activity and counteracting sVEGFR-1. Although related,
our method is not in the strict sense based on a cellular automata model. More specifi-
cally, it falls into the category of agent- or individual-based systems, which can be
defined as a generalization of the cellular automata approach.
Angiogenesis is under the control of a plethora of pro- and anti-angiogenic factors
[1] and is therefore a very complex phenomenon subjected to intense regulation. It
is sometimes difficult from biological assays alone to determine the net, global
effects of candidate molecules on angiogenesis. Computational approaches, such as
the one described here, can aid biologists in designing experiments and draw conclu-
sions. Alternatively, some molecules share both pro- and anti-angiogenic properties
and computational models may help to determine the dominant effect. Finally, this
effect is highly dependent on the concentration of the molecules and its vicinity, i.e.,
the amounts of pro- and anti-angiogenic molecules supposed to interact together to
dictate a pro- or anti-angiogenic signal. Again, computational models can help
researchers to estimate the concentration of molecules to be used in in vitro tests,
together with other factors that should be incorporated into the tests. We believe
that our present data on adenosine and sVEGFR-1 illustrate these limitations inher-
ent to in vitro tests.
Most relevant insights and advances
Our models are based on the dynamic interaction of cells and molecular entities
encoded as autonomous, discrete system components or agents. These locally-occur-
ring interactions are specified by a set of logical (if-then) rules that give rise to global,
emergent behaviour throughout thousands of time cycles and simulations. These and
alternative approaches are suitable to tackle the complexity and broad knowledge
scope of angiogenesis research, in general, and of a cardiovascular disease framework,
in particular. Our model was capable to generate visual quantitative patterns and pre-
dictions that are entirely derived from the system’s self-organizing properties, as well
as from adaptations to several stimuli. These features also make our approach
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in mathematical formalisms.
The main objective of our study was to assess the potential of the proposed approach
as a simulation-based exploratory tool. Thus, the implementation of a rule-based meth-
odology can also be justified by its openness and flexibility: it does not require the pre-
cise approximation of mathematical parameters, such as concentration rates, which are
needed in traditional reaction models. At this stage, this is particularly relevant due to
the relative lack of quantitative information to allow us to implement more detailed
models of the molecules investigated.
For constant VEGF values, added Ado can induce stronger (absolute) changes in net-
work area than those prompted by sVEGFR-1’s increases over comparable variation
scales (Figures 7 and 8). In each scenario the induced absolute changes (from mini-
mum to maximum areas) are notable: ~10% vs. ~68% for sVEGFR-1 and Ado variation
scenarios respectively. This offers quantitative evidence to further characterize the
angiogenesis hypothesis underlying our model. That is, VEGF’s pro-angiogenic effect
on a systems level is enhanced by its local interplay with Ado, regardless of the pre-
sence of sVEGFR-1. Conversely, the global inhibitory power of sVEGFR-1 is condi-
tioned to the absence of Ado in local neighbourhoods.
We also presented a comparative assessment of the resulting models in relation to in
vitro experiments using human ECs. Although we cannot consider this as an experi-
mental validation of our approach, it offers preliminary evidence about its potential to
recapitulate several angiogenesis-like principles and patterns. Researchers can also
interrogate our model using different types of quantitative “what-if” queries based on
specific molecular parameters controlling ECs network growth and sprouting. Perhaps
most important, the model has improved our knowledge of Ado-mediated angiogenesis
in different biologically-relevant conditions.
The partial disagreement observed in the in silico vs. in vitro comparisons (the effect
of the combined action of added Ado and VEGRF-1), also provides us with significant
insights. The reported discrepancy may be explained by the relative small number of
in vitro experiments conducted. Also we cannot exclude the possibility of the influence
of other angiogenic factors present in cell culture medium that were not considered in
the in silico approach and that could interact with the added molecules. In addition, it
has to be considered that the three in vitro replicates were independent experiments
with different cell batches and conditioned medium from different cultures of primary
human cells (therefore containing different mixtures of angiogenic factors and cells
with different genetic background). These limitations support the vessel network area
variability detected in our preliminary in vitro results. Nevertheless, these results may
also highlight knowledge gaps in our computational model and prior hypotheses. This
also means that our results are already pointing to a specific aspect of Ado-mediated
angiogenesis that requires further investigations. This may imply the need for a re-for-
mulation of our core hypothesis about the role of Ado in the conditions studied here.
For example, this could require us to consider the incorporation of additional molecu-
lar entities into our model, such as those whose interaction are required in control
conditions or in the specific context of added Ado/sVEGFR-1.
Thus we can postulate that, although computational experiments may not account
for all observed in vitro behaviour, the models investigated here and future extensions
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tionally help researchers to make informed decisions on future experimental research.
The latter is based on the idea that these models can explore experimental settings
that can be more expensive or challenging to deploy in a systematic manner in the
“wet lab”.
Limitations and future research
A possible limitation of algorithmic, discrete models is the difficulty in defining specific
model parameters, such as concentration values. Our models underwent a verification
phase that resulted in responses that were consistent with expected control responses.
In this case the selection of parameters was guided by experimentally-meaningful rela-
tionships, such as concentration value proportions between molecular entities in con-
trol conditions. The challenge of numerical specification of parameters in algorithmic,
discrete models is not as great as that posed in the design of traditional, mathematical
models (i.e., differential equations).
One of the possible next steps in our research is to achieve a tighter linkage between
in silico and in vitro experiments, which can cover alternative qualitative and quantita-
tive predictive features. Although in this study we focused on a phenotypic characteri-
zation based on vessel network areas, it is important to design models that can provide
a better approximation to the graphical details (detailed vascular patterning) of the spe-
cific in vitro conditions. Solutions, however, will inevitably depend on the biological
questions asked by the researchers, as well as on the biological cultures and assays
available. We would also expect to implement additional in vitro experiments with lar-
ger sample sizes or alternative protocols.
As a first step in a proof-of-concept investigation, we focused on global quantitative
relationships between in silico and in vitro models. In particular, the total area of the
resulting networks represented the quantitative criterion to test our models and estab-
lish correlations between them. This is a critical modelling factor that needs to be
addressed before refining models to assess other quantitative or qualitative relation-
ships. Qualitative aspects, such as a more detailed reproduction of visual patterns, will
also require additional in vitro work. In this study, for example, we applied an
endothelial microtube formation assay as a first in vitro evaluation step. In contrast to
our in silico models, in this assay an artery segment was not used as the initial vascular
network. A more accurate correlation of qualitative features, e.g., shape of the net-
works, could involve the implementation of an assay in which an artery segment is
used as the seed vascular network. Building on the outcomes of this investigation, in
the future we aim to implement new in vitro experiments to assess additional quantita-
tive and qualitative correlative indicators.
Our model synthesizes experimentally-feasible mechanisms at the cellular level.
Thus, future applications may involve more specific behaviours such as protein secre-
tion, detachment of ECs from existing vessels and EC proliferation in response to dif-
ferent types of chemoattractants. The simulations reported here excluded the
specification of endogenous Ado because in our in vitro conditions its levels tend to be
negligible in comparison to the levels of added Ado. Although future research may
soften this assumption by allowing the incorporation of endogenous Ado, we do not
expect this simplification to have a significant influence on the overall findings of this
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sufficiently shorter to keep entity levels constant. As part of future research, it would
be important to implement simulations whose time scales can more accurately corre-
spond to in vitro scales. Moreover, our model can be adapted to represent time-depen-
dent degradation of molecular entities, such as Ado, whose half-life is known to be
short. Future research will also attempt to model more realistic spatial and entity geo-
metrical aspects.
The rationale behind the 2-D grid is that it approximates the spatial representation
of a typical in vitro angiogenesis assay, i.e. 2-D models based on Matrigel. Variations of
the topological assumptions, e.g. moving to a 3-D model, should not be expected to
cause significant differences at the systems response level. Nevertheless, we would
agree that this will naturally increase the computational complexity of our model
implementations. In addition, this would require new, typically more expensive ways,
to validate our results in vitro. Although at this stage we are focusing on a 2-D grid
model due to its biological relevance and existing technical constraints, as part of
future work we will definitely consider extensions of our model to accommodate varia-
tions in spatial constraints.
The intrinsic assumptions of our model logic were those at the core of our biological
hypotheses, which in turn were motivated by prior knowledge. Hence, at this stage it
would be difficult to point to a specific logical aspect that could accurately explain the
observed discrepancy. Possible explanations will be obtained as new model configura-
tions (hypotheses) will be tested using our simulation system. In the light of the out-
comes of this pilot study, we are considering the possibility of refining our models by
incorporating additional entities and logical relations not encoded here. However, this
effort is still in a planning stage and will require significant biological literature exami-
nation and model requirements analysis. A crucial requirement for selecting a new
hypothesis for computational modelling will be its biological viability and potential
relevance. Furthermore, this will also depend on the identification of feasible strategies
and resources for the in vitro validation of the resulting in silico predictions.
Conclusions
Despite the need for achieving deeper levels of biological detail and for additional wet-
laboratory work to further assess our findings, our approach offers a new knowledge
discovery-support tool. Such a tool can improve our understanding of a clinically-rele-
vant problem at a systems- and multi-cell level. This and related algorithmic modelling
approaches will be vital to cost-effectively engineer novel patient-intervention and drug
discovery strategies in a systems biomedicine era. This research exemplifies the appli-
cation of discrete computational models to explore hypotheses and inform biological
research, and provides a foundation from which to enable deeper understandings of
angiogenesis.
Additional material
Additional file 1: Model responses to different numbers of cycles/simulation. Data plot.
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